Physician profile
Michael Anthony Serna
NPI 1548675135
$837.42
in general payments reported to CMS, 2019-2025
11 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.78 · 2021: $36.35 · 2022: $123 · 2023: $299 · 2024: $116 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $656.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $139.18 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $130.42 | 2021-2024 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $119.17 | 2023-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $93.15 | 2022-2023 | Spravato, Invega Sustenna |
| Bioxcel Therapeutics, INC. | $78.48 | 2023-2025 | Igalmi |
| Otsuka America Pharmaceutical, INC. | $69.44 | 2022-2025 | Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $68.05 | 2021-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $65.46 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $28.28 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.01 | 2023 | |
| Sunovion Pharmaceuticals INC. | $21.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Serna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.